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ABSTRACT
This DURIP grant made possible major technological advances at the three sites of the AFOSR PRET Center (University of Pennsylvania, Harvard University and Stanford University), substantially improving the Center's capability to study the neurobehavioral and neurobiological deficits associated with sleep deprivation and jet lag, and the development of countermeasures, in the context of simulated sustained operations. At Stanford University, a state-of-the-art pre-clinical sleepwake bioassay technology (SCORE-2000) was developed and employed for the clinically predictive testing of countermeasures in animals. At the University of Pennsylvania and at Harvard University, integrated systems for the on-line measurement of a range of physiological and neurobehavioral variables in humans were purchased, installed, tested and operationalized. Thus, from pre-clinical animal studies to application in human laboratory studies, the DURIP grant considerably streamlined and expanded the PRET Center's efforts to identify, evaluate and transition countermeasures to deficits associated with sleep deprivation and jet lag. 
SUBJECT TERMS
University of Pennsylvania executive summary report:
The equipment requested in the proposal was purchased and incorporated into the basic scientific research of the AFOSR PRET Center. This research involves the development of technologies to overcome the neurobehavioral and neurobiological deficits associated with sleep deprivation and jet lag. In addition, this equipment facilitated the research and related science education of a multi-university, multi-disciplinary research initiative (MURI).
Specifically, this equipment grant facilitated the integration of new ambulatory and online technology for integrated monitoring of human physiology (EEG, EOG, EMG, ECG) and neurobehavioral alertness (vigilance performance, eyelid closures) for early indentification and prevention of performance failures due to sleep loss and circadian phase during simulated sustained operations.
The purchased polysomnographical units were tested extensively in laboratory protocols, and based on our experiences some modifications were made by the manufacturer to further optimize data quality. Together with the core body temperature recorders and the actigraphs, for which only a limited amount testing was found to be needed, the polysomnographical units currently provide a fully operational complement of human physiological measures, which are being intregrated into the recently renewed AFOSR PRET Center research.
All computer software and hardware to handle the various recordings and data analyses are in place. While the PERCLOS monitors for eyelid closures are undergoing calibration at this time, they are also being integrated into the recently renewed AFOSR PRET Center research, utilizing the purchased computer hardware to full capacity. Finally, a computer server was installed to handle the increased amount of data gathered in our simulated sustained operations research.
In conclusion, this DURIP equipment grant has substantially improved and refined our measurements of an increased range of human physiological and neurobehavioral variables in the context of sleep loss and circadian rhythmicity during simulated sustained operations -from recording to data management, reduction and analysis.
Publications:
Hughes, RJ, Vandongen, H, Dinges, D, Rogers, N, Wright, KP Jr., Edgar, DF, Czeisler Harvard Medical School executive summary report:
In the period covering 9/99 -9/00, we received and implemented the use of equipment for the measurement of wake-sleep actigraphy and light exposure recording, minute-by-minute samples of core-body temperature; neurobehavioral performance testing, polysomnographic and waking EEG recording equipment.
The equipment acquired under the DURIP provided the state-of-the-art infrastructure that allowed us to obtain research funds for a pilot grant assessing the novel wake-promoting drug modafinil in a simulated jet-lag night-shift protocol. This pilot study provided important preliminary work for our currently funded AFOSR PRET investigation entitled "Homeostatic & Circadian Regulation of Wakefulness During Jet Lag and Sleep Deprivation: Effect of WakePromoting Countermeasures". The equipment purchased is also currently used in our AFOSR PRET study.
Data collected with this equipment will be incorporated into a model of alertness and performance currently being developed to counteract fatigue associated with Air Force missions. 
Future Applications
In addition to the licensed use by Hypnion, Inc. (mentioned above), SCORE-2000™ will be used in academic settings to enhance basic research efforts sponsored both by DOD and PHS. The SCORE-2000™ system will not only revolutionize the efficiency and accuracy of the SCORE Sleep-Wake Bioassay process, but will make possible further preclinical developments based on important recent findings. Whereas out AFOSR sponsored research has previously focused on differentiating the advantages and disadvantages of methamphetamine, caffeine and modafinil as a therapeutic countermeasures for impaired alertness, new research made possible by this equipment grant will allow us to investigate the therapeutic utility of a much wider range of new and atypical wake-promoting therapeutics. For example, our research partners at Gliatech, Inc. would like us to continue to assess a series of novel H3 histaminergic antagonist medications with wake-promoting actions. These compounds are particularly exciting because they not only act on well documented natural histaminergic wake-promoting mechanisms in the brain, but also may enhance cognitive performance. We believe this new-generation series of wake promoting therapeutics can be targeted for mission critical applications where sleepiness and impaired cognitive performance due to sustained operations could lead to catastrophic loss. Gliatech, Inc. also anticipates major applications for this series of medications in Alzheimer's disease which is characterized by cognitive deterioration and severe sleep disorders.
Additional preclinical discovery made possible by the new SCORE-2000™technolgy includes studies of Pemoline (Cylert®) and a family of selective dopamine reuptake blockers that shows great promise for sustaining wakefulness without producing incremental or synergistic increases in compensatory sleep drive (a serious problem with currently available psychostimulants). We have recently found that Pemoline, a medication often used for attention deficit hyperactivity disorder (ADHD), and a family of selective dopamine reuptake blockers (DARBs) can produce sustained wakefulness that is completely uncoupled from the mechanisms that normally produce sleepiness and compensatory hypersomnolence associated with sleep deprivation. Our findings suggest that we can indeed tap into the most fundamental mechanisms of sleep regulation and pharmacologically control the physiological processes responsible for sleepiness. Before this remarkable finding can be extrapolated for use in humans, however, studies of drug interaction with pre-existing sleep loss, efficacy measures as a function of time of day are vitally needed, and animal modeling of drug effect and side effects during pharmacologically enhanced sustained operations are needed. Similar studies are also needed for numerous promising new candidate compounds we have identified in the selective dopamine reuptake blocker class. Based on our preliminary data, compounds including GBR12909, GBR12783, 4'4"-difluoro-3oc(diphenylmethoxy) tropane, and amineptine each hold promise as novel "somnolytic" wake-promoting therapeutics. As noted for pemoline, however, several studies designed to: i.) validate the therapeutic efficacy of these drugs in sleep-loss and jet-lag scenarios, and ii.) assess novel drug medication interaction with commonly used over-thecounter and food stimulants (e.g., caffeine and theophylline) will be needed before these compounds can be safely advanced for human clinical trials.
Finally, it must be mentioned that, due to the very high data throughput of the new SCORE-2000 system, it will be possible to begin assessment of drug interaction at the preclinical level and assess the predictive utility of such interaction in humans. This is a critical area in drug development and a growing liability concern for industry. Based on preliminary evidence, we believe the SCORE-2000 technology holds promise for predicting undesirable drug interaction on sleep-wakefulness at the pre-clinical stage of drug development. This information will then advise the pharmaceutical industry prior to the costly efforts associated with clinical trials.
Because the need for safe and effective wake-promoting therapeutics is go great, the SCORE-2000™ Sleep-Wake Bioassay System is virtually certain to advance our preclinical discovery over the next decade, leading to the development of novel somnolytic medications. Indeed, these medications could revolutionize sleep disorders medicine and we currently know it.
Patents
There are no patents associated with SCORE-2000™ and Stanford University has declined interest in such an effort citing anticipated difficulty with patent enforcement. The software component of the technology was procured as a license agreement with Stanford Software Systems (a company that is not affiliated with Stanford University). Under this agreement, Stanford University purchased an Exclusive license to use SCORE-2000™, however the copyright was vested in Stanford Software Systems under terms of the Purchase and Sale agreement. Mr. Rand Wheatland dba Stanford Software Systems transferred the SCORE-2000 copyright to Dr. Dale Edgar, who in turn issued unrestricted sublicense authority to Stanford University.
